Bloomberg Open Interest 05/01/2025

Strong tech earnings set the stage for an eighth straight day. GM slashes its guidance with up to a $5 billion dollar hit from tariffs; Kohl's fires its CEO who's been on the job for less than 5 months; Eli Lilly falls after CVS announced a plan to drop its blockbuster weight-loss drug Zepbound, making rival Wegovy more widely available. We talk AI Infrastructure with Marc Ganzi, the CEO of DigitalBridge. Vlad Tenev, Robinhood CEO is in the C-Suite talking cryptocurrencies and the company's strong earnings. (Source: Bloomberg)

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Insider

2 hours ago

• Business Insider

Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Sarepta Therapeutics (SRPT) and Eli Lilly & Co (LLY)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insulet (PODD – Research Report), Sarepta Therapeutics (SRPT – Research Report) and Eli Lilly & Co (LLY – Research Report) with bullish sentiments. Confident Investing Starts Here: Insulet (PODD) In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Buy rating on Insulet. The company's shares closed last Friday at $303.15. According to Marcus is a 4-star analyst with an average return of 9.1% and a 52.8% success rate. Marcus covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Bausch + Lomb Corporation, and Inspire Medical Systems. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insulet with a $337.56 average price target, a 10.9% upside from current levels. In a report issued on June 16, Truist Financial also initiated coverage with a Buy rating on the stock with a $365.00 price target. See Insiders' Hot Stocks on TipRanks >> Sarepta Therapeutics (SRPT) In a report issued on June 20, Anupam Rama from J.P. Morgan maintained a Buy rating on Sarepta Therapeutics, with a price target of $30.00. The company's shares closed last Friday at $20.08. According to Rama has 0 stars on 0-5 stars ranking scale with an average return of -6.9% and a 37.7% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Ultragenyx Pharmaceutical, and Kiniksa Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sarepta Therapeutics with a $44.96 average price target, implying an 115.4% upside from current levels. In a report issued on June 5, Scotiabank also upgraded the stock to Buy with a $80.00 price target. Eli Lilly & Co (LLY) Bernstein analyst Courtney Breen maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $1100.00. The company's shares closed last Friday at $762.73. According to Breen is a 2-star analyst with an average return of 0.5% and a 33.3% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Gilead Sciences, and Merck & Company. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $999.57 average price target, implying a 27.2% upside from current levels. In a report issued on June 6, Bank of America Securities also maintained a Buy rating on the stock with a $1000.00 price target.

Yahoo

9 hours ago

• Yahoo

Eli Lilly (NYSE:LLY) Advances Orforglipron GLP-1 Therapy To Phase 3 With Positive Results

Eli Lilly recently announced positive Phase 3 trial results for orforglipron, the first oral small molecule GLP-1 receptor agonist showing superior A1C reduction in type 2 diabetes patients, which aligns with a 7% share price increase over the last month. This, along with new offerings for Zepbound and strategic collaborations, potentially supported the company's stock performance. While the broader market showed a flat trajectory, the company's developments likely added weight to its upward trend. The ongoing lawsuit and acquisition rumors were less likely to significantly influence its share performance this month. We've identified 2 warning signs with Eli Lilly (at least 1 which is significant) and understanding the impact should be part of your investment process. The latest GPUs need a type of rare earth metal called Terbium and there are only 24 companies in the world exploring or producing it. Find the list for free. The recent advancements announced by Eli Lilly, particularly the positive Phase 3 trial results for orforglipron, could have significant implications for the company's growth narrative. These developments, alongside the expansion of its product offerings in oncology and immunology, bolster the potential for revenue acceleration. As the company progresses with new drug approvals and scales manufacturing capabilities, it strengthens its stance in crucial therapeutic areas. The strategic expansion is tied to analyst forecasts that anticipate higher revenue and profit margins, reinforcing Lilly's commitment to capturing larger market share and enhancing future earnings potential. Over the past five years, Eli Lilly's total shareholder return, including share price and dividends, skyrocketed by nearly 396.74%. This considerable increase underscores the company's capacity for growth, contrasting with its underperformance compared to the US Pharmaceuticals industry over the last year, where the industry saw an 11.2% decline. Analysts expect Eli Lilly's annual earnings growth to significantly outpace the broader market, aligning with the company's ongoing investments and strategic initiatives. These promising developments are expected to impact revenue and earnings forecasts positively. Anticipated growth in revenue by 20.2% annually over the next three years could support the company's trajectory toward higher earnings, which analysts project to reach US$31.7 billion by 2028. The current share price, US$775.12, shows a discount to the consensus analyst price target of US$981.63, indicating potential room for appreciation if the company meets expectations. However, investors should perform their own assessments to ensure alignment with these forecasts. Click here to discover the nuances of Eli Lilly with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:LLY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Forbes

14 hours ago

• Forbes

EV U.S. Sales Lag Will Reprieve ICE, Boost Hybrids

ICE versus EV getty Every other new car bought by Americans in 2030 was supposed to be electric, but as the Trump Administration clears away EV incentives and targets, the total is likely to be less than half that and offer a lifeline to gas powered vehicles and hybrids That represents an unexpected new lease of life for the likes of GM , Ford, and Stellantis brands like Chrysler, Dodge, Jeep and Ram and their combustion technology. They were highly dependent on internal combustion engines and were either slow or reluctant to embrace EVs. A combination of tax credit rollbacks, emissions standards delays and the removal of the Biden Administration and its call for a 50% share for EVs in the new car market in 2030 is a boost for ICE. Manufacturers will also be busily raising production of hybrids, plug-in hybrids, and extended range electric vehicles*. Consultants Roland Berger put it this way in a recent report. 'Delayed adoption of BEVs (EVs) will have cascading effects on the entire automotive value chain, prolonging profitability challenges for electrification-focused players and extending the window of opportunity for ICE-focused legacy players,' the report said. Analysts have been scrambling to slash their forecasts for U.S. EV sales in 2030. Investment bank UBS says EVs will only reach 24% of the new car market or 2.7 million vehicles. Four months ago UBS was predicting 32%. U.S. EV market share is currently around 10%. BloombergNEF now predicts 27%, down from almost 48%. Investment researcher Jefferies is even lower at about 20% along with Roland Berger. Roland Berger was projecting around 40% under Biden's watch. 'Actions taken by the Trump administration to loosen light vehicle emissions standards have effectively halved our forecast for U.S. electric vehicle adoption by 2030 – We now only expect about 20% BEV sales by 2030,' said Brandon Boyle, Senior Partner and Americas Automotive lead at Roland Berger. This compares starkly with Europe's ambitions. The European Union has decreed EV sales shall reach about 80% of new vehicle sales by 2030 on the way to 100% by 2035. Given current market share is barely 20% in Europe, some major humble-pie eating is on the cards. The Mazda MX-30 R-EV is an extended range electric vehicle equiped with a small rotary gasoline ... More engine (Photo by Sjoerd van) Getty Images / Sjoerd van der Wal 'The U.S. market has different dynamics (than Europe): more rural driving, less dense urban cores, and a political environment that could shift depending on the 2028 (Presidential) election,' said Curt Hopkins, CEO of MCQ Markets . MCQ Market says it is a FinTech firm making high-value assets accessible and investable. 'I wouldn't call it a comeback for ICE, but it's not going away overnight either. Hybrids and plug-in hybrids are still very much part of the transition-especially for consumers who aren't quite ready for a full battery-electric experience. Expect those to play a meaningful but gradually shrinking role through the decade,' Hopkins said. Bernstein Research analyst Daniel Roeska said at some point EV demand will accelerate again. Maybe after the 2028 election or after 2030. 'It (the expectation) won't be 50% for a long while,' Roeska said in an interview. '(General Motors, Ford and Stellantis) agreed that U.S. electrification will take a lot longer. Even if the target picture of high EV share in the U.S. has not changed, (manufacturers) are waking up to the fact that they must improve EV profitability without significant volume growth and maintain investments into legacy products for longer,' Roeska said in a recent report. Hard to bet against Tesla Tesla is the current EV market leader and despite a huge increase in competition and lower expectations for the overall market, is expected to retain its ascendancy, said MCQ's Hopkins. 'It's hard to bet against Tesla. They're vertically integrated, have a dominant brand, and continue to lead on software and over-the-air updates. As long as they maintain that pace of innovation, they'll likely still be the U.S. leader in 2030,' said Hopkins. According to Kelley Blue Book , the Tesla Model Y led the U.S. EV market in 2024 with sales of 373,000 and a market share of 28.6%, the Tesla Model 3 was next with 190,000 (14.6%). Then came the Ford Mustang Mach-E with 52,000 or 4.0%. 'That said, keep an eye on some dark horses. Chinese automakers like BYD and NIO are getting serious about international expansion, and if trade policy allows, they could become a factor in the U.S. by the end of the decade.' The All-Electric Ford Mustang Mach-E (Photo by) Getty Images 'Among the legacy automakers, Ford, GM, and Volkswagen have all shown real progress. Their ability to scale EV production and leverage existing dealer networks could help them close the gap, especially as more affordable models hit the market,' according to Hopkins. Twice the power, half the weight, half the cost He doesn't expect any game-changing battery technology before 2030, just incremental improvements in battery design. The long- promised solid-state battery revolution – twice the power, half the weight, half the cost - isn't close as researchers stumble over mass production techniques. And the trouble is that as consumers hear about this huge, imminent improvement, they are likely to be wary of buying an EV, and risk having its residual value torpedoed by game-changing technology. That could put the skids on EV demand as 2030 approaches. More bad news for EV makers came this week, courtesy of a survey of 15,000 drivers around the world by oil-giant Shell. The survey showed drivers in America are becoming more reluctant to switch to EVs from ICE vehicles. Those considering switching fell three percentage points to 31% compared with a year ago. In Europe, the reluctance was more ominous given the massive EV targets set for 2030. According to the survey, 41% said they would consider switching to an EV, down from 48% last year. Shell operates 75,000 charging points around the world including the U.S., Europe and China. *(Hybrids use computer power to combine for maximum efficiency with gasoline engines, and have relatively small batteries. They provide maybe 1 mile of electric-only driving. PHEVs have bigger batteries which can be charged independently and can provide up to 75 miles of electric-only transport. EREVs, like the Mazda MX30 R-EV, use small combustion engines to charge the battery. The MX30 R-EV is always powered by electricity.)